Experimental basis of the therapy of Parkinson's disease and the cholinergic-dopaminergic equilibrium in basal brain nuclei.
D000818:Animals; D001058:Apomorphine / Q000494:pharmacology; D001480:Basal Ganglia Diseases / Q000139:chemically induced; D001522:Behavior, Animal / Q000187:drug effects; D001921:Brain / Q000503:physiopathology*; D002217:Carbachol / Q000494:pharmacology; D002421:Caudate Nucleus / Q000502:physiology; D003342:Corpus Striatum / Q000502:physiology; D004298:Dopamine / Q000502:physiology*; D006801:Humans; D009069:Movement Disorders / Q000503:physiopathology; D010275:Parasympathetic Nervous System / Q000503:physiopathology*; D010277:Parasympathomimetics / Q000494:pharmacology; D010300:Parkinson Disease / Q000188:drug therapy*; D010302:Parkinson Disease, Secondary / Q000139:chemically induced; D011817:Rabbits; D051381:Rats; D011954:Receptors, Dopamine / Q000187:drug effects; D013239:Stereotyped Behavior / Q000187:drug effects; D013378:Substantia Nigra / Q000502:physiology; D013569:Synapses / Q000502:physiology; D005680:gamma-Aminobutyric Acid / Q000502:physiology
D010277:Parasympathomimetics; D011954:Receptors, Dopamine; D005680:gamma-Aminobutyric Acid; D002217:Carbachol; D001058:Apomorphine; D004298:Dopamine